The Case for Funding Our National Drug Safety Surveillance System

Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO This editorial reflects the views of the author and should not be construed to represent FDA's views or policies. E.H.M. is a Special Government Employee and advises the FDA on issues of drug safety and risk management. During the past 36 months, E.H.M. received research grant support from Janssen Pharmaceuticals and reimbursement for consulting services from Janssen Pharmaceuticals, Merck, Merck Foundation, and the PhRMA Foundation. Reprints: Elaine H. Morrato, DrPH, MPH, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Mail Stop B119, 13001 East 19th Place, Aurora, CO 80045. E-mail: [email protected]

Family medicine · Foundation (evidence) · Government (linguistics) · Health care · Library science · Political science · Public health · Public relations · Reimbursement · Medicine · Nursing · Pharmaceutical industry and healthcare · Pharmaceutical studies and practices · Pharmacovigilance and Adverse Drug Reactions

• The Potential Return on Public Investment in Detecting Adverse Drug Effects

  Krista F Huybrechts, Rishi J Desai et al.•Medical Care•2017

  Incluir item